Keyword: InFLAMES Flagship

This page displays contents related to the keyword.

On the Mission to Unleash the Full Power of ICB in Cancer

10.05.2023

Through immunotherapies utilising Immune Checkpoint Blockers (ICB), advanced solid cancers can today be treated with unprecedented efficacy. However, not all patients respond positively to these treatments. InFLAMES researcher, Docent Carlos Rogerio Figueiredo and his team are working to uncover the underlying causes of this resistance to ICB. They focus on patients suffering from malignant melanomas and lung cancers as main research models. 

InFLAMES Corporate Corner delves into the possibilities of novel techniques in medical research

28.04.2023

New technologies aim to find revolutionary ways to diagnose, treat and prevent diseases. The second InFLAMES Flagship Corporate Corner of 2023 will focus on the topic from the perspectives of both researchers and companies.  The InFLAMES Corporate Corner will take place on 11th May from 12 to 16 at the Visitor and Innovation Centre Joki in Turku. The event is open to all.

Promising Results from a Nasal Pertussis Vaccine Against Whooping Cough

24.04.2023

A new nasal pertussis vaccine against whooping cough has shown promising results. The vaccine was shown to be safe and to work against whooping cough in a study conducted in healthy adults. Professor Qiushui He and Project Researcher Alex-Mikael Barkoff from the InFLAMES research flagship of the University of Turku participated in the study. The research article was published in the esteemed medical journal Lancet.